HIV increases markers of cardiovascular risk: Results from a randomized, treatment interruption trial

AIDS

Volumn 23, Issue 8, 2009, Pages 929-939

  Calmy, Alexandra ^a   Gayet Ageron, Angèle ^a   Montecucco, Fabrizio ^a   Nguyen, Alain ^a   Mach, Francois ^a   Burger, Fabienne ^a   Ubolyam, Sasiwimol ^a,b   Carr, Andrew ^a,c   Ruxungtham, Kiat ^a,b,d   Hirschel, Bernard ^a   Ananworanich, Jintanat ^a,b,e  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c ST VINCENT S HOSPITAL   (Australia)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e South East Asia Research Collaboration with Hawaii ^*  (Thailand)

Author keywords

Cardiovascular risk; HIV; HIV RNA replication; Inflammation; Marker

Indexed keywords

ADIPONECTIN; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; D DIMER; DIDANOSINE; EMTRICITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; LAMIVUDINE; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; TENOFOVIR; VASCULAR CELL ADHESION MOLECULE 1; VIRUS RNA;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; RNA, VIRAL; THAILAND;

EID: 67049172548     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832995fa     Document Type: Article

References (48)

1. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviraf therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999; 353:863-868.
2. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34.
3. Lewden C, May T, Rosenthal E, et al., for the ANRS EN19 Mortalité Study Croup and Mortavic1. Changes in causes of death among adults infected by HIV between 2000 and 2005: the 'Mortalite 2000 and 2005' surveys (ANRS EN 19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
4. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
5. Sterne JA, May M, Bucher HC, Ledergerber B, Furrer H, Cavassini M, et al. HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Intern Med 2007; 261:255-267.
6. El Sadr WM, Lundgren JD, Neaton JD, Cordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
7. Sudapo I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF. Cardiovascular disease in HIV infection. Am Heart J 2006; 151:1147-1155.
8. Wang TJ, Gona P, Larson MG, ToflerGH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-2639.
9. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. J Am Coll Cardiol 2008; 52:569-576.
10. Papasavvas E, Azzoni L, Pistilli M, Hancock A, Reynolds G, Gallo C, et al. Increased soluble vascular cell adhesion mole-cule-1 plasma levels and soluble intercellular adhesion mole-cule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy. AIDS 2008; 22:1153-1161.
11. Montecucco F, Macn F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009; 48:11-22.
12. Ferroni P, Martini F, Riondino S, La Farina F, Magnapera A, Ciatti F, Guadagni F. Soluble P-selectin as a marker of in vivo platelet activation. Clin Chim Acta 2009; 399:88-91.
13. Kreuzer KA, Rockstroh JK, Kupfer B, Spengler U. Endogenous levels of C-C chemokines MIP-1 alpha, MIP-1 beta, and RANTES do not reflect the disease course in HIV-seropositive individuals. Int J Clin Lab Res 2000; 30:163-168.
14. Ardigo D, Assimes TL, Fortmann SP, Go AS, Hlatky M, Hytopoulos E, et al., ADVANCE Investigators. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol Genomics 2007; 31:402-409.
15. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Øie E, Otterdal K, et al. Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008; 28:1909-1919.
16. Montes de Oca Arjona M, Pérez Cano R, Orozco MJ, Martín Aspas A, Guerrero F, Fernández Gutiérrez Del Alamo C, Girón-González JA. Absence of favourable changes in circulating levels of interleukin-16 or beta-chemokine concentration following structured intermittent interruption treatment of chronic human immunodeficiency virus infection. Clin Microbiol Infect 2005; 11:57-62.
17. Brown PA, Angel JB. Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. J Immune Based Ther Vaccines 2005; 3:3.
18. Kell R, Haunstetter A, DenglerTJ, Zugck C, Kübler W, Haass M. Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. Eur Heart J 2002; 23:70-78.
19. Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
20. Montecucco F, Mach F. New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. Clin Interv Aging 2008; 3:341-349.
21. Kuo LT, Yang Nl, Cherng WJ, Verma S, Hung MJ, Wang SY, et al. Serum interleukin-6 levels, not genotype, correlate with coronary plaque complexity. Int Heart J 2008; 49:391-402.
22. Stylianou E, Aukrust P, Kvale D, Muller F, Frøland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression - down-regulatory effect of potent antiretroviral therapy. Clin Exp Immunol 1999; 116:115-120.
23. Tziakas DN, Chalikias GK, Kaski JC, Kekes A, Hatzinikolaou El, Stakos DA, et al. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: a factor analysis approach. Atherosclerosis 2007; 193:196-203.
24. Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV lipodystrophy. AIDS 2007; 21:895-904.
25. Soderberg S, Colquhoun D, Keech A, Yallop J, Barnes EH, Pollicino C, et al. Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond) 2009; 33:123-130.
26. Goldstein BJ, Scalia RG, Ma XL. Protective vascular and myocardial effects of adiponectin. Nat Clin Pract Cardiovasc Med 2009; 6:27-35.
27. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465.
28. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83:356-362.
29. Friis-Moller N, Sabin CA, Weber R, d'Arminio MA, El Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
30. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185:456-462.
31. Golledge J, Clancy P, Jamrozik K, Norman PE. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation 2007; 116:2275-2279.
32. Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H, et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006; 26:2147-2152.
33. Parissis JT, Venetsanou KF, Kalantzi MV, Mentzikof DD, Karas SM. Serum profiles of granulocyte-macrophage colony-stimulating factor and C-C chemokines in hypertensive patients with or without significant hyperlipidemia. Am J Cardiol 2000; 85:777-779; A9.
34. Rothenbacher D, Muller-Scholze S, Herder C, Koenig W, Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26:194-199.
35. Thakore AH, Guo CY, Larson MC, Corey D, Wang TJ, Vasan RS, et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framing-ham Heart Study). Am J Cardiol 2007; 99:1598-1602.
36. Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr Opin Cardiol 2003; 18:471-478.
37. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsoufis C, Marinou K, et al. Differences in inflammatory and thrombotic markers between unstable angina and acute myocardial infarction. Int J Cardiol 2007; 115:203-207.
38. Wolk R, Berger P, Lennon RJ, Brilakis ES, Davison DE, Somers VK. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007; 28:292-298.
39. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes 2000; 49:485-491.
40. Stenvinkel P, Lindholm B, Heimburger M, Heimburger O. Elevated serum levels of soluble adhesion molecules predict death in predialysis patients: association with malnutrition, inflammation, and cardiovascular disease. Nephrol Dial Trans-plant 2000; 15:1624-1630.
41. Leghmari K, Bennasser Y, Tkaczuk J, Bahraoui E. HIV-1 Tat protein induces IL-10 production by an alternative TNF-alpha-independent pathway in monocytes: role of PKC-delta and p38 MAP kinase. Cell Immunol 2008; 253: 45-53.
42. Lehmann MH, Walter S, Ylisastigui L, Striebel F, Ovod V, Geyer M, et al. Extracellular HIV-1 Nef increases migration of monocytes. Exp Cell Res 2006; 312:3659-3668.
43. Coll B, Parra S, Alonso-Villaverde C, Aragones G, Montero M, Camps J, et al. The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke 2007; 38:2477-2484.
44. Zhong Y, Smart EJ, Weksler B, Couraud PO, Hennig B, Toborek M. Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation oftheRassignaling. J Neurosci 2008; 28:7788-7796.
45. Grunfeld C, Kotler DP, Hamadekhe R, Tiernen A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27-31.
46. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al., for the INSIGHT SMART Study group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
47. Du Clos TW. Function of C-reactive protein. Ann Med 2000; 32:274-278.
48. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al., JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.